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Abstract: Multiple sclerosis (MS) is a debilitating autoimmune disorder. Currently, there is a lack of
effective treatment for the progressive form of MS, partly due to insensitive readout for neurodegeneration. The recent development of sensitive assays for neurofilament light chain (NfL) has made it a
potential new biomarker in predicting MS disease activity and progression, providing an additional
readout in clinical trials. However, NfL is elevated in other neurodegenerative disorders besides
MS, and, furthermore, it is also confounded by age, body mass index (BMI), and blood volume.
Additionally, there is considerable overlap in the range of serum NfL (sNfL) levels compared to
healthy controls. These confounders demonstrate the limitations of using solely NfL as a marker to
monitor disease activity in MS patients. Other blood and cerebrospinal fluid (CSF) biomarkers of
axonal damage, neuronal damage, glial dysfunction, demyelination, and inflammation have been
studied as actionable biomarkers for MS and have provided insight into the pathology underlying
the disease process of MS. However, these other biomarkers may be plagued with similar issues
as NfL. Using biomarkers of a bioinformatic approach that includes cellular studies, micro-RNAs
(miRNAs), extracellular vesicles (EVs), metabolomics, metabolites and the microbiome may prove to
be useful in developing a more comprehensive panel that addresses the limitations of using a single
biomarker. Therefore, more research with recent technological and statistical approaches is needed to
identify novel and useful diagnostic and prognostic biomarker tools in MS.
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1. Introduction
Multiple sclerosis (MS) is a chronic, immune-mediated inflammatory demyelinating disease of the central nervous system (CNS) that affects more than 2 million people
around the world, with the highest prevalence among those between the ages of 20 and
40 years [1,2]. There are currently many treatment options to reduce the relapse rate and
neuroinflammation in relapsing-remitting multiple sclerosis (RRMS), the most common
clinical subtype of MS; however, after 10–20 years, most patients with RRMS progress
to secondary progressive multiple sclerosis (SPMS) with eventual axonal and neuronal
degeneration [3]. Primary progressive multiple sclerosis (PPMS) is another progressive
form of MS, and along with SPMS, there are few effective treatments that can prevent the
disability progression in these two clinical subtypes. Ocrelizumab and Siponimod, though
approved for progressive disease, are only marginally effective in SPMS and PPMS patients
and are more effective in progressive patients with inflammatory disease activity.
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Unlike rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) used to diagnose
rheumatoid arthritis (RA), there is no serologic diagnostic test for MS [4]. When a patient
exhibits symptoms classic of MS, they are tested to exclude other diseases, such as lupus,
Lyme disease, and B12 deficiency. It is also sometimes difficult to determine whether a
patient with MS is experiencing a true relapse or a pseudo-relapse confounded by infection
and comorbidities [5]. Not only are biomarkers for MS diagnosis and true relapses lacking,
but biomarkers for disease progression and treatment response are also largely lacking.
The latter has been hindered by the heterogeneity in the immune signatures in the patient
population, affecting the development of effective treatment for progressive disease [6,7].
Although it is effective to use the annualized relapse rate to determine treatment
efficacy in RRMS, due to the insensitivity of the Expanded Disability Status Scale (EDSS), it
is much more challenging to quantify disability progression in progressive MS. The Multiple
Sclerosis Functional Composite (MSFC), 25-foot walk test (T25FW), 9-hole peg test (9-HPT),
and the symbol digit modality tests (SDMT) have been incorporated in trials to increase the
sensitivity [8]. It is crucial to find sensitive biomarkers that can predict disease progression.
An ideal biomarker should have diagnostic and prognostic value, correlate with specific
disease activity such as relapse or progression, respond to treatment, and essentially be
useful in clinical trial outcomes. Additionally, an ideal biomarker should be non-invasive,
safe, accurate, reproducible, cost-effective, and easily detectable in patients [9].
2. Classic Diagnostic Markers
2.1. Magnetic Resonance Imaging
Currently, the most reliable and routinely used diagnostic tool for MS is magnetic
resonance imaging (MRI). Specifically, T2-weighted MRI images are used to identify both
white matter and gray matter MS lesions. The presence of these lesions demonstrates
inflammation with mixed pathology of neuro-axonal damage and demyelination [10].
However, confirming relapses and active inflammation in RRMS is done by detecting
gadolinium-enhancing T1 lesions on MRIs. The presence of enhancing brain lesions has
also been associated with long-term disability and brain atrophy, with new or enlarging
lesions being correlated with disability progression and cerebral atrophy. However, routine
MRIs do not specifically detect damage to neurons and axons, which is most strongly
correlated with long-term disability in MS [3,11,12]. Routine MRIs lack sensitivity and
specificity for neurodegeneration; measuring cortical thickness at an individual level may
be challenging with interpersonal variability [13].
2.2. Spinal Fluid Analysis
The main advantage of using cerebrospinal fluid (CSF) over blood to measure biomarkers is that it more accurately reflects the inflammatory profile of the CNS [14]. CSF biomarkers have the advantage of being more sensitive compared to clinical or MRI assessments,
especially in the setting of low-grade disease activity in MS. Among some patients whose
disease was considered inactive by clinical scales and/or MRI, CSF neurofilament light
chain (cNfL) and immunoglobulin (Ig)G-index were found to be significantly elevated [15].
IgG index is the ratio of IgG to albumin in the CSF compared to that in the serum [16].
Having a ratio greater than 0.7 usually results in a diagnosis of MS. Analyzing the CSF for
markers of inflammation such as oligoclonal bands and IgG index is helpful in diagnosis,
but oligoclonal bands and IgG index are not ideal biomarkers for predicting relapse and
progression. Measuring oligoclonal bands is not very sensitive as it can be challenging to
determine how many bands are present. Additionally, they are not very specific, as anything causing chronic inflammation can result in elevated oligoclonal bands [17]. However,
some studies have shown that IgM-type oligoclonal bands are associated with increased
MS activity, increased retinal axonal loss, decreased retinal nerve fiber layer, and more
aggressive disease progression during early stages of RRMS [16,18–21].
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2.3. Evoked Potentials
Evoked potentials (EPs), including visual evoked potentials (VEPs), somatosensory
evoked potentials (SSEPs), and brainstem auditory evoked response (BAERs), are noninvasive techniques that can assess neural conduction in various pathways. It is performed
by stimulating the respective system, with a scalp electrode over the corresponding cortex measuring the latency and amplitude. Prolonged latency indicates damage due to
demyelination, which can be a useful tool and aid in diagnosing MS and assessing specific
pathways [22]. There is also a proposed role of EPs in the prognosis of MS and the treatment
response, but this is not yet widely clinically applicable [23].
3. Other Imaging Techniques
3.1. Optical Coherence Tomography
Optical coherence tomography (OCT) is a non-invasive assessment that uses light
to scan the retina and optic disc to measure the degeneration of the optic nerve after
inflammation. This has been proposed as a model to examine neurodegeneration. Measures
have been incorporated into clinical trials for neuroprotective agents. The thickness of
the retinal nerve fiber layer (RNFL) directly measures optic nerve axonal loss, which is
associated with a persistent visual deficit. RNFL loss is associated with brain atrophy,
neurological impairment, and disease duration [24].
3.2. Magnetic Transfer Imaging
Magnetic Transfer Imaging (MTI) can help provide information on the severity of the
disease by differentiating between MS lesions and tracking the evolution of acute lesions.
This is done by calculating the magnetic transfer ratio (MTR), which provides information
about tissue integrity by its ability to exchange magnetization with mobile water molecules.
This can elucidate the level of intact white matter, which has been shown to be associated
with the extent of demyelination and axonal loss [25–27]. MTR can also be calculated for the
optic nerve, with a lower value indicating decreased RNFL and axonal degeneration [28].
3.3. Magnetic Resonance Spectroscopy
Magnetic Resonance Spectroscopy (MRS) can be used to determine the extent of CNS
cellular metabolism via a non-invasive technique measuring several biochemical molecules.
It measures N-acetylaspartate levels, which have been implicated in neuronal and axonal
loss. MS lesions around normal-appearing white matter and cortical grey matter have
shown lower levels of N-acetylaspartate (NAA) [29], which has been associated with disease
progression and disability [30]. Additionally, choline is measured to determine whether
there has been an increase in rotational cell membrane components, which is usually seen
with demyelination or gliosis. It also measures glutamate levels, which correlate with acute
inflammation, and γ-aminobutyric acid (GABA), which has been found to be decreased in
SPMS [31].
3.4. Diffusion Weighted Imaging
Diffusion weighted imaging (DWI) helps to differentiate between various CNS pathologies, such as infections, strokes, tumors, and neurodegeneration. This is done by evaluating
water’s apparent diffusion coefficient in the brain, which is associated with changes in
cell structure and white matter tracts. Specifically, it is helpful in evaluating ischemic
cerebrovascular accidents and is limited in its role in diagnosing MS as it is hindered by its
inability in measuring extent of tissue loss in MS lesions [32,33]. Additionally, this form of
imaging has a high risk of false positives [34].
3.5. Diffusion Tensor Imaging
Diffusion tensor imaging (DTI) can elucidate more information about MS pathogenesis
than current MRI techniques. It can measure water’s three-dimensional diffusion and
provide information on axial diffusivity (DA), radial diffusivity (RD), mean diffusivity
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(MD), and fractional anisotropy (AF) [33]. DA can be used to examine axonal loss and
degeneration, with a higher value seen with later MS disease progression. RD can be used
to examine the extent of demyelination [35–38]. MD is associated with tissue changes that
occur because of the breakdown of the blood-brain barrier and injuries that occur after
the restoration of the blood-brain barrier (BBB), allowing it to be a useful parameter in
assessing for the MS onset and relapse [39]. Failure analysis can be performed to determine
whether there is an increase in global water diffusion in white matter tracts and a decrease
in disorganized fibers due to MS pathology [40].
4. Biomarkers of Axonal Damage
4.1. Neurofilament Light Chain
Over the past three decades, many assays have been developed to detect neurofilament
light chain (NfL) levels. Neurofilaments are cytoskeletal proteins released from damaged
axons into the CSF and the blood. Studies have also found that increased cNfL levels
are correlated with increased CD4+ T lymphocytes, which have been implicated in the
inflammation seen in MS [41], and progression of RRMS to SPMS [42]. Early studies have
found that cNfL levels of MS patients are increased during active relapse and acute relapse
compared to healthy controls [43]. There is a positive correlation between cNfL and serum
NfL (sNfL) in MS patients [44–46], with cNFL levels 42-fold higher than sNFL levels [45].
A benefit to using sNfL levels as opposed to cNfL levels is that serum levels are easier to
obtain than conducting a spinal tap or lumbar puncture on a patient to retrieve CSF. Over
the last few years, single molecular array (SiMoA) has made measuring NfL concentration
levels more clinically relevant.
In general, MS patients also had higher sNfL levels before treatment compared to
healthy controls. With disease-modifying treatment, sNfL levels were lower [45]. Treatments with higher efficacies have also been shown to reduce NfL levels more effectively
than traditional treatment options. Additionally, levels of sNfL have been associated with
T2 lesion volumes [47]. Some reports showed strong correlations between sNFL levels and
the number of active lesions present on MRI scans [48,49]. However, some patients have
several active MRI lesions with low sNfL, and some have no MRI lesions with high sNfL,
indicating that other confounding factors can result in high sNfL levels. Therefore, patients
will still require MRI scans [49]. Studies have also shown that brain and spinal cord atrophy
may be positively correlated with sNfL levels. One study showed a reduction in the brain
and spinal cord volume over five years, with a greater reduction for those with higher sNfL
baseline levels [50].
A recent study assessed the prognostic value of sNfL obtained close to the time of MS
onset with long-term clinical outcomes [51]. sNfL were tested from samples collected at
the time of diagnostic workup. After 15 or more years of follow-up, the baseline median
sNfL at higher levels had a significantly higher hazard ratio of developing an EDSS ≥ 4.
There was a trend toward a higher median sNfL level in patients with progressive disease,
but this did not reach significance. Another study showed no association between higher
long-term EDSS scores and higher sNfL levels at disease onset nor an association between
sNfL levels and relapse activity overtime in MS patients [47].
A study of United States (U.S.) military personnel with MS and their matched controls
assessed whether sNfL levels are elevated before the clinical onset of MS [52]. The sNfL
levels were higher in cases of MS patients compared to controls. In the group with two
pre-symptomatic samples, the levels were higher in MS patients closer to the onset of
symptoms (median increase of 1.3 pg/mL per year), with no significant difference in the
samples from the matched controls over time. In the second group where samples were
collected before and after symptom onset, most had a significant increase in sNfL levels
between the two points (median level of 25.0–45.1 pg/mL), suggesting that neuroaxonal
degradation starts years prior to the onset of MS and emphasizing the importance of
early treatment. A follow-up study further demonstrated that in a cohort of U.S. military
personnel, an infection of Epstein-Barr Virus (EBV) increased the risk of MS by 32-fold.
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However, this was not observed for other viral infections. sNFL levels were also found to
be elevated after EBV seroconversion [53].
The sNfL level is a valuable biomarker at the group level. However, it may be
challenging to use in a clinical setting to assess whether an individual has MS. Many studies
showed that there is a large overlap between the baseline sNfL level of patients with MS
and their controls who may have migraine or conversion disorder [47]. Using NfL levels as
a biomarker for MS relapse is not specific, as NfL levels are elevated in infections and many
neurodegenerative [54] and neurological disorders in addition to MS. sNfL is positively
correlated with age due to age-related neuronal degeneration and has been found to be
higher in older patients during relapse [45]. This may be a significant confounding variable
because progressive MS patients tend to be older patients. Plasma NfL (pNfL) levels are
also negatively correlated with body mass index (BMI) and blood volume [55]. Therefore,
the search for a predictive and diagnostic biomarker for MS continues because sNfL cannot,
itself, be individually used to determine MS disease activity. Another application of sNfL
is to monitor inflammatory disease activity and distinguish actual relapses from pseudorelapses. Several studies have shown that sNfL levels are elevated in relapse in an MS
population. However, there is a significant overlap in sNfL levels in RRMS patients,
highlighting the limitations of sNfL in identifying relapses [56].
4.2. Tau Protein
Tau protein, which has been implicated in Alzheimer’s disease, is responsible for
stabilizing axonal microtubules and has been found to be released upon neuronal damage,
allowing it to be measured in the CSF [57,58]. In MS, it can be used as a biomarker for
axonal loss [30]. One study found tau protein levels to be correlated with the severity of
clinical symptoms [59], while another found that those with higher CSF tau protein levels
tend to have a quicker disease progression measured by a one-point increase in EDSS
score and can be used to predict the time to next relapse [60]. However, one study with
patients with clinically isolated syndrome (CIS), which is defined as the first neurological
episode of inflammation or demyelination in at least one site in the CNS lasting greater than
24 h [61], did not find a statistically significant difference in tau concentration compared
to the control group nor a statistically significant correlation between tau concentration
and EDSS scores [62]. However, another study found that tau protein was correlated with
EDSS in both CIS and RRMS patients and that higher levels of tau were correlated with
the conversion of CIS into clinically definite MS. They also found that tau protein level
was associated with the number of T2-lesions on MRI [63]. Another study also found tau
protein concentrations in the CSF of MS patients of all clinical subtypes to be similar to
those of controls [64].
4.3. Amyloid-Precursor Protein
Amyloid precursor protein (APP) has also been implicated in Alzheimer’s disease but
nevertheless may be associated with MS. It is produced by astrocyte cells during demyelination and can be located in reactive glial cells during de- and remyelination [65]. MS patients
present with higher levels of APP compared to controls and axons that are positive for APP
in MS patients have been shown to be correlated with CNS lesion development [66].
4.4. Tubulin Beta
Tubulin beta (TUBβ) is a subunit of tubulins, which are heterodimeric proteins that
make up microtubules. The neuron development and regeneration have been associated
with increased production of the class II tubulin isotype. Specifically, one study found that
CSF TUBβ was increased in patients with MS compared to patients with other neurological
diseases [67]. A summary of this biomarker and the ones discussed above in this section
can be found in Table 1.
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Table 1. Biomarkers of Axonal Damage.
Potential
Biomarker

Study Population (n)

Sample

Results

RRMS (65), SPMS (10),
PPMS (20)

CSF

Correlated with RRMS
progression to SPMS [42]

RRMS (41), SPMS (25),
controls (50)

CSF

Increased during active and acute relapse in
MS patients compared to healthy controls [43]

CSF, serum

Strong associated between CSF and serum
levels; serum levels lower with
disease-modifying treatment; serum
levels positively correlated with age and
higher in older patients during relapse and
associated with higher risk of relapse and
EDSS worsening [45]

RRMS (435), SPMS (54),
PPMS (25), CIS (93)

Serum

Lower levels associated with active treatment,
with larger decreases in NfL levels with
high-potency treatments. Associated with T2
lesion volume over time; no association
between higher levels at disease onset and
higher long-term EDSS scores nor any
association with relapse activity overtime;
large overlap between the baseline level in
MS patients and controls who may have
migraine or conversion disorder [47]

RRMS (15)

Serum

Associated with clinical or MRI
disease activity [48]

SET cohort: RRMS (163)
GeneMSA cohort:
RRMS (179)

Serum

Lower levels associated with lower
probability of recent imaging disease activity;
higher levels associated with higher number
of active MRI lesions [49]

RRMS (35), PPMS (17),
CIS (15)

Serum

Higher baseline levels associated with higher
hazard ratio of developing EDSS ≥ 4
after 15+ years [51]

MS (60)

Serum

Levels were increased six years prior
to onset of MS [52]

MS (955)

Serum

Levels were elevated only
after EBV seroconversion [53]

MS (25), controls (67)

CSF

Correlated with prominence
of clinical symptoms [59]

Probable or confirmed
RRMS (32)

CSF

Correlated with quicker disease progression
and predicts time of next relapse [60]

CIS (21), controls (20)

CSF, serum

No difference between CIS patients and
controls; no correlation with EDSS scores [62]

RRMS (38), CIS (52),
controls (25)

CSF

Correlated with EDSS in both CIS and RRMS
patients; higher correlated with conversion of
CIS into clinically defined MS; associated
with the number of T2-lesions on MRI [63]

RRMS (32), SPMS (2),
PPMS (4), CIS (12),
controls (19)

CSF

Similar levels among all clinical
sub-groups and controls [64]

CIS (20), CDMS (43),
controls (56)

CSF

Similar concentrations between those with
demyelinating disease and controls [68]

RRMS (62), SPMS (3)
PPMS (16), CIS (48),
RIS (13), controls (87)

NfL

Tau

Possible Utility

Predictive, prognostic,
treatment response

Predictive, prognostic
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Table 1. Cont.
Potential
Biomarker

Study Population (n)

Sample

Results

Possible Utility

Associated marker

Associated marker

APP

MS (6), controls (6)

CSF

Higher in MS patients compared to controls;
MS patients with axons that are positive for
APP are correlated with CNS lesion
development [66]

TUBβ

RRMS (24), SPMS (7),
PRMS (1), PPMS (1)

CSF

Higher in MS patients than patients with
other neurological diseases [67]

n = sample size; NfL = neurofilament light chain; APP = amyloid precursor protein; TUBβ = tubulin beta;
MS = multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple
sclerosis; PPMS = primary progressive multiple sclerosis; CIS = clinically isolated syndrome; RIS = radiologically
isolated syndrome; CDMS = clinically defined MS; PRMS = progressive relapsing MS; CSF = cerebrospinal
fluid; EDSS = Expanded Disability Status Scale; MRI = magnetic resonance imaging; EBV = Epstein-Barr Virus;
CNS = central nervous system.

5. Biomarkers of Neuronal Damage
5.1. 14-3-3 Protein
14-3-3 protein, which is present in neurons, can be measured in the CSF of both patients
with MS and those with Creutzfeldt-Jakob disease [64]. However, the role of 14-3-3 protein
in MS is inconsistent. Studies have found that 14-3-3 protein in the CSF is associated
with more severe disability, more extensive involvement of the spinal cord, and quicker
progression to MS or disease progression [68–70]. Early accumulation of 14-3-3 protein in
the CSF may be correlated with decreased rates of recovery. However, some studies have
difficulties detecting 14-3-3 protein in the CSF, with one only detecting it in 2 patients out of
22 MS patients [71] and another detecting it in only one patient out of 21 CIS patients [62].
5.2. Neuron Specific Enolase
Concentrations of neuron specific enolase (NSE), an enzyme found in neurons and
axons that can be used to estimate neuronal density, have been found to be increased in
both the CSF and serum of patients suffering from trauma, hypoxic brain injury, or cerebral
bleeding [72–74]. One study found a decrease in serum and CSF NSE in patients with CIS
compared to healthy controls [62], with some studies showing either no change [43,74] or a
negative correlation between plasma NSE levels and EDSS and Multiple Sclerosis Severity
Score (MSSS) [75]. A summary of this biomarker and the ones discussed above in this
section can be found in Table 2.
Table 2. Biomarkers of Neuronal Damage.
Potential
Biomarker

14-3-3

Study Population (n)

Sample

Results

CIS (21), controls (20)

CSF

Levels are undetectable in the majority [62]

CIS (20), CDMS (43),
controls (56)

CSF

Associated with greater disease disability and rate of
disease progression [68]

RRMS (10), SPMS (7),
PPMS (2), controls (5)

CSF

Associated with more severe disability and extensive
involvement of spinal cord [69]

CIS (38)

CSF

Associated with quicker progression to MS and
predictive of EDSS ≥ 2 [70]

MS (22)

CSF

Levels are undetectable in the large majority [71]

Possible Utility

Prognostic
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Table 2. Cont.
Potential
Biomarker

NSE

Study Population (n)

Sample

Results

RRMS (41), SPMS (25),
controls (50)

CSF

No difference between MS patients and controls [43]

CIS (21), controls (20)

CSF, serum

Lower in CIS patients compared to controls [62]

RRMS (19), SPMS or
PPMS (2)

Serum

Normal range in patients with MS [74]

RRMS (25), SPMS (23),
PPMS (16)

Plasma

Negative correlated with EDSS and MSSS score [75]

Possible Utility

Prognostic

NSE = neuron specific enolase; MSSS = Multiple Sclerosis Severity Score.

6. Biomarkers of Glial Dysfunction
6.1. Glial Fibrillary Acidic Protein
Glial fibrillary acidic protein (GFAP) is expressed by mature astrocytes and has been
found to be increased in plaques of MS patients, indicating damage to astrocytes [76,77].
Patients with SPMS had higher CSF GFAP levels than those with RRMS [78]. Additionally,
higher CSF levels of GFAP are associated with greater disabilities and relapse [79].
6.2. S100β Protein
There have been reports of an increase in serum and plasma levels of S100β protein, a
subunit of the S100 protein that is found in glial cells, in MS [80], with the highest levels
in patients with PPMS or SPMS [79]. Examples of S100β functions include maintaining
astrocyte integrity, assisting with neuronal proliferation, and differentiating oligodendrocytes. During acute exacerbations in patients with RRMS, S100β levels have also been
shown to be increased; however, the window is small as S100β levels were no longer
increased in patients who had acute exacerbations prior to one week ago [80]. Changes
in S100β have also been seen in patients with cerebral ischemia of amyotrophic lateral
sclerosis [81,82]. However, a study did not find a statistically significant difference in CSF
and serum S100β protein concentration between CIS patients and healthy controls, but
this may be confounded by some samples being obtained more than one week after the
acute exacerbation. The same study also did not find any significant correlation between
S100β protein concentration and EDSS score [62]. No differences in plasma S100β protein
concentration between various clinical subtypes of MS have also been described [75], along
with no difference in CSF S100β concentration between patients with MS and controls [43].
6.3. Anti-Aquaporin 4 Antibodies
Astrocytes express aquaporin-4 (AQP4) to help establish homeostasis in the CNS
by moving water through cell membranes. However, studies have found that AQP4 is
undetectable in patients with MS. This is a measure to help with the difficult task of
differentiating MS from neuromyelitis optica (NMO), which is a rare condition that also
presents with demyelination of the optic nerve and spinal cord [83,84].
6.4. Nitric Oxide
Nitric oxide (NO) has been found to be increased in both the serum and CSF of MS
patients [85,86]. It inhibits cytochrome C oxidase, resulting in impaired mitochondrial
function due to decreased energy production [87]. Byproducts of NO degradation can
destroy mitochondria, leading to prominent damage in MS lesions. It can also increase the
effects of apoptosis on neurons and glial cells and allow the passage of pro-inflammatory
cells into the CNS by increasing blood-brain barrier permeability [88]. A summary of this
biomarker and the ones discussed above in this section can be found in Table 3.
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Table 3. Biomarkers of Glial Dysfunction.
Potential
Biomarker

GFAP

S100β

AQP4

NO

Study Population (n)

Sample

Results

MS (503), controls (252)

CSF

Patients with SPMS had higher levels
than those with RRMS [78]

RRMS (20), SPMS (21),
PPMS (10), controls (51)

CSF

Associated with greater disabilities and relapse [79]

RRMS (41), SPMS (25),
controls (50)

CSF

No difference between MS patients and controls [43]

CIS (21), controls (20)

CSF, serum

No difference between CIS patients and controls; no
correlation with EDSS score [62]

RRMS (25), SPMS (23),
PPMS (16)

Plasma

No difference between various clinical
subtypes of MS [75]

RRMS (20), SPMS (21),
PPMS (10), controls (51)

CSF

Highest levels in order of PPMS, SPMS, then RRMS,
with all higher than controls [79]

RRMS (9 with acute
exacerbations, 3 stable),
chronic progressive
(8 with acute
exacerbations, 3 stable)

Plasma

Acute exacerbations results in higher levels [80]

MS (144), NMO (37)

Serum

Only detectable in 4 out of 144 MS patients but
detectable in 21 out of 37 NMO patients [83]

RRMS (27), SPMS (6),
PPMS (5), controls (14),
NMO (24)

Serum

Undetectable in all MS patients and controls, but
detectable in 14 out of 24 patients with NMO [84]

RRMS (8), SPMS (8),
PPMS (1), controls (8)

CSF, serum

Increased in MS patients compared to controls [85]

MS exacerbation (24),
MS remission (17),
MS progression (20),
tension headache (8),
controls (11)

CSF

Increased in MS patients compared to controls [86]

Possible Utility

Prognostic

Prognostic

Diagnostic

Associated
marker

GFAP = glial fibrillary acidic protein; AQP4 = anti-aquaporin 4; NO = nitric oxide; NMO = neuromyelitis optica.

7. Biomarkers of Myelin Biology/Demyelination
7.1. Myelin Basic Protein
Myelin basic protein (MBP) is produced by the oligodendrocytes from the central
nervous system and has been found to be increased in the CSF of patients with MS and
correlated with EDSS scores [89]. One study found that MS patients with an acute exacerbation had higher levels than those with slower progressive MS and even higher than
those in remission [90]. However, using MBP is challenging, as demyelination lesions can
be remyelinated by MBPs in the CSF [91,92].
7.2. Myelin Oligodendrocyte Glycoprotein
Myelin oligodendrocyte glycoprotein (MOG) associated disease, a newly recognized
disorder, is differentiated from NMO and MS by the presence of MOG antibodies in the
serum. Additionally, differences have been found in CSF myeloid cell types in subjects
with neuroinflammation, which included those with MS and anti-MOG disorder [93]. A
summary of this biomarker and the ones discussed above in this section can be found in
Table 4.
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Pro-inflammatory cells, T helper (Th) 1 and Th17 cells, produce cytokines, such as
interleukin (IL)-17, interferon (IFN)-γ, and tumor necrosis factor (TNF)-α, while anti-inTable 4. Biomarkers of Myelin Biology/Demyelination.
flammatory cells, regulatory T (Treg) and Th2 cells, produce IL-10 and IL-4. Measuring
these cytokines and cellular changes can reflect the disease type, demonstrated by a study
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(n)
Sample
Results
Possible
Utility
in pediatric
MS
where serum levels of anti-inflammatory
cytokine IL-10 were
predictive
of relapse compared to other pro- and anti-inflammatory cytokines [94]. Therefore, imRRMS (31), CIS (18)
CSF
Correlated with EDSS scores [89]
mune signatures, along with the above markers all together as a composite, can be used
Acute exacerbation
of MS differentiate underlying
MS patients
with an
acute exacerbation
had activity
higher (Figure
Prognostic
to further
disease
pathology
and disease
1).
(15), remission (19), slow
CSF
levels than those with slower progressive MS and
Additionally, C-X-C motif chemokine ligand (CXCL) 13 has been found to be correprogressive form (13)
even higher than those in remission [90]
lated with worse prognosis and exacerbations in RRMS and conversion of CIS to MS.
Distinct myeloid cell types if subjects with
However,
[95]. One
Diagnostic
RRMS (2), anti-MOG
(1) CXCL13
CSF is non-specific as patients with infections also had high levels
neuroinflammation [93]
study found that CSF and plasma levels of eotaxin-1 (CCL11) were associated with disease
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= myelin
basic protein;
MOG = myelin
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especially
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Additionally, C-X-C motif chemokine ligand (CXCL) 13 has been found to be correlated
with worse prognosis and exacerbations in RRMS and conversion of CIS to MS. However,
CXCL13 is non-specific as patients with infections also had high levels [95]. One study
found that CSF and plasma levels of eotaxin-1 (CCL11) were associated with disease
duration, especially in patients with SPMS. They also found C-C motif chemokine ligand
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(CCL) 20 to be associated with disease severity and CSF levels of IL-12B, macrophage
inflammatory protein (MIP)-1a, cluster of differentiation (CD)5, and CXCL9, and plasma
levels of oncostatin (OSM) and hepatocyte growth factor (HGF) to be associated with
MS [96]. Serum IL-6 has also been found to be correlated with the age of onset for MS
patients and was detected at a higher rate in MS patients compared to controls [97].
Immune signatures may also predict treatment response or prognosis of MS patients.
Most biomarker studies have focused on IFN-β, where there is a wide variation in response
to this therapy. Neutralizing antibodies (Nabs) against IFN-β are associated with treatment
failure [98], but they only partially explain non-responsiveness. Serum cytokine profiles
have shown immunologically distinct subgroups of MS, and these subgroups may stratify
treatment response to IFN-β [6].
8.2. Soluble CD40L
We took a novel approach by using age and disease duration-matched non-progressive
benign multiple sclerosis (BMS) patients to look for progression-specific biomarkers using
Luminex array. We found plasma soluble CD40L (sCD40L) was significantly increased in
SPMS compared to non-progressive benign MS (BMS). While the combination of sCD40L
and monocyte chemoattractant protein 1 (MCP1)/CCL2 could be used to distinguish
RRMS from SPMS, elevated sCD40L and IFN-γ levels are best at differentiating SPMS
from BMS [99]. We further demonstrated in a Phase I proof-of-concept study that antiCD40L monoclonal antibody (mAb) IDEC-131 (Toralizumab) was safe and feasible for
treating MS [100]. Immunological analysis showed no depletion of lymphocyte subsets.
Instead, an increase in CD25+/CD3+ and CD25+/CD4+ ratio and a shift towards an antiinflammatory cytokine response were seen. In light of the fact that sCD40L was found to
be highly upregulated in SPMS compared to BMS, it further strengthens the importance of
this therapeutic target. A Phase II trial in MS using a next-generation anti-CD40L mAb,
SAR441344, will provide further insight into the role of the heightened level of sCD40L in
SPMS patients. We also showed that RNFL thickness deteriorates only mildly in BMS and
that T cells have upregulated IL-10 and leukemia inhibitory factor (LIF) and downregulated
IL-6 and neurotensin high affinity receptor 1 in BMS [101]. Therefore, comparison with nonprogressive MS is a useful approach to identify potential biomarkers and novel therapeutic
targets for disease progression. Future combinations of several biomarkers may be most
appropriate due to multifaceted changes of MS disease processes.
8.3. Chitinase-3-Like-1 Precursor
Chitinase-3-like-1 precursor (CHI3L1) has been found to be increased in the CSF of
many patients with CNS inflammatory diseases and is expressed by astroglia, normalappearing white matter, white matter plaques, and brain lesions in MS patients. Specifically,
serum and CSF levels were found to be increased with the disease stage and associated with
more rapid conversion to RRMS in CIS patients. Additionally, lower CSF levels were found
in patients with progressive MS compared to patients with RRMS [102]. However, another
study found that plasma levels of CH13L1 were increased in patients with progressive MS
compared to patients with RRMS and healthy controls. Higher plasma levels were also
associated with more relapses and T1 and T2-weighted lesion load and brain parenchyma
fraction in patients with MS [103]. Higher CSF levels have also been associated with
quicker development of disability and conversion into clinically defined MS (CDMS) in
CIS patients [104]. Serum levels of CHI3L1 have been found to be increased in groups of
patients unresponsive to IFN-β treatment [105].
8.4. Heat Shock Protein 70 and 90
Heat shock proteins (HSPs) are molecular chaperones, subdivided by molecular
weight, that help regulate homeostasis in the CNS [106]. HSP70, which is located in
the cytosol, is involved in the immune response by protecting against damage from stress
in both the cell membrane and intracellular space [107,108]. In MS, it can protect neurons
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and oligodendrocytes from apoptosis during inflammation, but extracellular HSP70 may
also play a role in inducing an immune response [109,110]. One study found that the
expression of HSPA1L gene that encodes for HSP70-hom protein was correlated with an
increased risk of MS development. Increased expression of HSP70-hom protein was also
correlated with disease severity [111]. Another study found that MS patients had higher
serum levels of HSP70 compared to healthy donors but lower levels than other inflammatory neurological diseases. The same study also found HSP70 levels to be higher in
CIS and RRMS compared to PPMS or SPMS [112]. In terms of treatment response, HSP90,
which produces anti-inflammatory cytokines and regulates toll-like receptor (TLR) 2 and
4 responses [113], has been shown to be more increased in the glucocorticoid receptor
complex of patients that are steroid-resistance than those that are steroid-sensitive [114].
8.5. Kappa Free Light Chain
Kappa free light chains (KFLC) are produced during the synthesis of antibodies by
plasma cells [20]. CSF Kappa free light chains have been proposed as an additional marker
to aid in the diagnosis of MS with comparable sensitivity and specificity to oligoclonal
bands, as they do not require a paired serum sample and provide a quick machine-operated
value instead of being reliant on visual evaluation [115]. Specifically, kappa free light chain
has been found to be increased in the CSF and serum of MS patients [116] and correlated
with disabilities in the future [117] and disease progression as CIS patients with higher CSF
levels of KFLC had an earlier conversion to clinical defined MS [118].
8.6. Human Endogenous Retroviruses
Human Endogenous Retroviruses (HERVs), which comprise about 8% of the human
genome, are usually dormant within the genome until they are triggered by an environmental factor. Their activation can result in the production of envelope proteins by HERV-W,
which appears to be involved in the pathophysiology of MS [119]. One study found that
the presence of the pol gene of a MS-associated retrovirus (MSRV), such as HERV-W, in the
CSF of early MS patients could point to a poorer prognosis. Specifically, they found that
although MS patients that were MSRV+ or MSRV− in the CSF at study entry had similar
EDSS scores, the scores were significantly different after six years. Patients in the MSRV+
were also found to have a higher annual relapse rate, along with two patients from this
group having developed the progressive form of MS, while none from the MSRV− group
did [120]. Therefore, more research on HERVs can prove to be beneficial as HERVs may
play a significant role in understanding the development of MS and may be targets for new
therapeutic remedies.
8.7. Uric Acid
Serum levels of uric acid, which has antioxidant properties, have been found to be
decreased in patients with MS. To elucidate whether this is due to patients being primarily deficient or due to uric acid’s peroxynitrite scavenging activity, one study measured
the serum urate levels of MS patients and those with other neurological diseases. They
found that the urate levels of MS patients were significantly lower than those with other
neurological diseases. However, no significant correlation was found between urate levels
and disease activity, duration, disability, or course, supporting the notion that urate levels
are primarily deficient in MS, resulting in the loss of protective effects against oxidative
agents [121]. One study using a two-sample Mendelian randomization in a genome-wide
association meta-analysis with 25 independent genetic variants strongly associated with
serum urate levels found that increased serum urate levels do not lead to an increased risk
of MS [122]. A summary of this biomarker and the ones discussed above in this section can
be found in Table 5.

Int. J. Mol. Sci. 2022, 23, 5877

13 of 27

Table 5. Biomarkers of Immunomodulation and Inflammation.
Potential
Biomarker

Study Population (n)

Sample

Results

RRMS (114), CIS (43)

Serum

Immunologically distinct subgroups of MS,
and these subgroups may stratify treatment
response to IFN-β [6]

Pediatric onset MS (40),
controls (11)

Serum

IL-10 is predictive of relapse [94]

RRMS (323), SPMS (40),
PPMS (24), CIS (79),
OIND (176), ONIND
(181), controls (14)

CSF

CXCL13 has been found to be correlated with
worse prognosis and exacerbations in RRMS
and conversion of CIS to MS [95]

CSF, plasma

Plasma and CSF levels of CCL11 is associated
with disease duration, especially in patients
with SPMS; CCL20 is associated with disease
severity and CSF levels of IL-12B, MIP-1a,
CD5, and CXCL9, and plasma levels of OSM
and HGF to be associated with MS [96]

Serum

IL-6 has been found to be correlated with age
of onset for MS patients and is detected at a
higher rate in MS patients compared to
controls [97]

Plasma

Significantly elevated in SPMS compared to
BMS and RRMS; MCP1/CCL2 and sCD40L
can be used together to differentiate between
RRMS and SPMS; IFN-γ and sCD40L can be
used together to differentiate between BMS
and SPMS [99]

CSF, serum

Strong expression in MS patients, especially
astrocytes and microglia in white matter
plaques. Increased with disease stage and
associated with more rapid conversion to
RRMS in CIS patients. Lower CSF levels in
progressive MS compared to RRMS [102]

RRMS (124), SPMS (30),
PPMS (66), controls (57)

Plasma

Increased in patients with progressive MS
compared to patients with RRMS and healthy
controls; higher levels were associated with
more relapses and T1 and T2-weighted lesion
load and brain parenchyma fraction in
patients with MS [103]

CIS (84)

CSF

Higher levels associated with quicker disease
conversion to clinically defined MS in CIS
patients [104]

RRMS (117)

Serum

Increased in groups of patients unresponsive
to IFN-β treatment [105]

Cytokines
MS (136), OND (35),
controls (49)

RRMS (39), controls (39)

sCD40L

RRMS (8), SPMS (32),
BMS (12), controls (5)

RRMS (38), progressive
MS (16), CIS (40),
controls (29)

CHI3L1

Possible Utility

Predictive, prognostic,
treatment response

Prognostic

Predictive, prognostic,
treatment response
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Table 5. Cont.
Potential
Biomarker

Study Population (n)

Sample

Results

Whole
blood

Expression of HSPA1L gene that encodes for
HSP70-hom protein was correlated with
increased risk of MS development; increased
expression of HSP70-hom protein was
correlated with disease severity [111]

RRMS (40), SPMS (19),
PPMS (9), CIS (26),
OIND (28), ONIND (41),
controls (114)

Serum

Higher HSP70 levels in MS compared to
healthy controls but lower than other
inflammatory neurological diseases;
Increased HSP70 levels in CIS and RRMS
compared to PPMS or SPMS [112]

Steroid-resistant MS (15),
steroid-sensitive MS (15)

Peripheral
blood

Increased HSP90 in the glucocorticoid
receptor complex of patients that are
steroid-resistance compared to those that are
steroid-sensitive [114]

RRMS (37), PPMS (4),
OND (368)

CSF, serum

Increased in MS patients [116]

RRMS (23), SPMS (28),
PPMS (6)

CSF

Correlated with future disability [117]

CIS (78), controls (25)

CSF

CIS patients with higher CSF levels of KFLC
had earlier conversion to clinical
defined MS [118]

CSF

MSRV+ MS patients had higher EDSS scores
compared to MSRV- MS patients at 6-year
follow-up. MSRV+ MS patients have a higher
annual relapse rate. Two patients in the
MSRV+ group developed the progressive
form of MS [120].

Serum

Uric acid levels are decreased in MS patients
compared to those with other neurological
diseases. No correlation was found between
urate levels and disease activity, duration,
disability, or course [121]

MS (191), controls (365)

HSP

KFLC

HERVs

MSRV+ MS (10),
MSRV- MS (8)

MS (124), OND (124)
Uric Acid
MS (61,667),
controls (86,806)

Serum

Possible Utility

Prognostic, treatment
response

Predictive, prognostic

Prognostic

Associated marker

Increased urate levels do not lead to an
increased risk of developing MS [122]

CHI3L1 = Chitinase-3-Like-1 Precursor; HSP = heat shock protein; KFLC = kappa free light chain; HERVs = human
endogenous retroviruses; OND = other neurological diseases; OIND = other inflammatory neurological diseases;
ONIND = other non-inflammatory neurological diseases; BMS = benign multiple sclerosis; MSRV = MS-associated
retrovirus; IL = interleukin; CCL = C-C motif chemokine ligand; MIP = macrophage inflammatory protein;
CD = cluster of differentiation; OSM = oncostatin; HGF = hepatocyte growth factor; MCP = monocyte chemoattractant protein.

9. Biomarkers for a Future Bioinformatic Approach
9.1. Proteomic Approach
It may prove to be useful to include sNfL levels in a panel of other biomarkers, as
discussed above, to help with prognosis in MS. Using a multiplex proteomic assay Olink
technology on 724 serum proteins, a panel of serum proteins including urokinase-type
plasminogen activator (uPA), kallikreins family of protease hK8, desmoglein-3 (DSG3),
along with NfL were identified to be more accurate in defining a relapse than using NfL
alone [123].
9.2. Cellular Studies
MS disease state and disease-modifying treatments (DMTs) were shown to affect the
adaptive immune system, particularly T and B cell subsets, through immunological studies

Int. J. Mol. Sci. 2022, 23, 5877

15 of 27

in MS patients [124]. The overall goal of all DMTs is to dampen the pro-inflammatory
response while boosting the anti-inflammatory response by enhancing Th2, Treg, and
regulatory B (Breg) cells [125]. DMTs were shown to increase Th2 and Treg cell populations
while decreasing the Th1 and Th17 response. More specifically, fumarate, such as dimethyl
fumarate (DMF), affected clusters of differentiation CD8+ more than CD4+, with a larger
reduction seen for effector memory T (Tem) cells and central memory T (Tcm) cells than
naïve T (Tn) cells [6,56,126], while sphingosine-1-phosphate (S1P) modulators affected CD4+
more than CD8+, with a larger reduction seen for Tn and Tcm than Tem. Additionally, the
anti-CD20 monoclonal antibodies specifically depleted B cells [127].
Additionally, the expression and signaling of nuclear factor kappa beta (NFkB), a
transcription factor involved in the regulation of the innate and adaptive immune system,
has been found to be correlated with relapses in MS [128,129] and to be different between
patients with RRMS and progressive MS (PMS). One study analyzing CD3+ T cells from
RRMS patients discovered that out of 43 differentially expressed genes between acute
relapse and complete remission, abnormal NFkB gene expression in T cells correlated most
significantly with MS relapse [128]. DMTs and corticosteroids, both mainstay MS therapies,
have been shown to block NFkB signaling. One study found that after methylprednisolone
pulse therapy, patients with MS had significantly lower levels of DNA-binding p65 NFkB
subunits than healthy controls. This demonstrates that corticosteroids result in a lower
level of transcriptionally active pro-inflammatory NFkB in MS patients [130]. Another
study also found that DMF treatment in MS patients decreased p65 transcriptional activity
in NFkB signaling via a decrease in phosphorylation and nuclear translocation. DMF can
also suppress extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stressactivated kinase 1 (MSK1), which has been shown to further decrease NFkB signaling. By
inhibiting these pathways, DMF can inhibit dendritic cell maturation and the differentiation
of T cells into Th1 and Th17 subtypes [131].
9.3. Transcriptomic Approach
Future technology with single-cell RNA sequencing (sc-RNA seq) may allow researchers to compare the heterogeneity of RNA transcriptomes of individual cells within a
population in addition to information about gene expression to discover future biomarkers
for MS [132]. For example, using sc-RNA seq in MS, researchers have been able to further
examine CSF and blood leukocytes using single-cell transcriptomics because there is increased transcriptional diversity in both specimen types. They found an increase in CSF
follicular T cells that may be promoting the expansion and infiltration of B cells into the
CNS in animal models, increasing the severity of MS, whereas no significant differences in
cell composition were found in the blood compared to controls [133]. Another study found
an increase in CSF polyclonal IgM and IgG1 B cells polarized towards an inflammatory,
memory, and plasma cell phenotype, along with no detection of EBV [134].
9.4. Micro-RNA Molecules
Non-coding single-stranded micro-RNA (miRNA) molecules can be measured in the
CSF and serum of MS patients via polymerase chain reaction (PCR) techniques. miRNAs are
dysregulated in the immune system and CNS of MS patients, meaning different miRNAs
can be either upregulated or downregulated in MS patients, altering gene expression of
various mRNA transcripts [135,136]. Specifically, in peripheral blood mononuclear cells
(PBMCs) and white matter lesions in the brain of MS patients, miR-19a, miR-21, miR-22,
miR-142-3p, miR-146a, miR-146b, miR-155, miR-210, miR-233, and miR-326 are upregulated.
miR-15a, miR-19a, miR-22, miR-210, and miR-223 are additionally upregulated in regulatory
T cells (Tregs) and in the plasma and blood cells of MS patients. However, miR-15a, miR15b, miR-181c, and miR-328 are downregulated [137]. One study found that there is an
upregulation of serum miRNAs that promote anti-inflammation and pro-regenerative
polarization in MS patients. In contrast, they found that miR-155, which promotes proinflammatory states, was downregulated in both primary progressive MS (PPMS) and
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RRMS. These findings are potentially explained by monocytes attempting to counteract the
inflammation in the CNS. However, in some MS patients, especially those with progressive
MS, there is a downregulation of miR-124, which promotes an anti-inflammatory state.
This implies that in progressive MS, there is an absence of homeostatic monocyte control.
This study also found that miR-23a, miR-30c, miR-125a, miR-146a, and miR-223 were
upregulated in both RRMS and PPMS patients, but that miR-181a was only increased in
RRMS [138]. Studies have also found that CSF levels of miR-181c [139] and miR-150 [140]
are associated with an earlier conversion of CIS to MS. Additionally, miR-150 has been
found to be upregulated in MS patients compared to controls [140].
9.5. Extracellular Vesicles
Extracellular vesicles (EVs) can be broken down into microvesicles and exosomes
based on size. Microvesicles are usually 100–1000 nm, and exosomes are 50–150 nm.
Exosomes can be used to communicate between cells and travel large distances in the body.
Thus, they can be used to monitor MS disease progression and activity as well as therapeutic
treatment [141]. Exosomes can be released from T cells to regulate antigen presenting cells
via miRNAs contained within the exosome [142] and act as proinflammatory regulators in
rheumatoid arthritis, Grave’s disease, and in MS [143–145]. EVs are found to be increased
in the CSF and plasma of MS patients and have different molecular compositions compared
to EVs from healthy individuals [141]. A study found that patients with RRMS had
significantly altered miRNAs compared to controls, specifically an increase in miRNA let-7i
in exosomes [146]. A higher number of total exosomes from the CSF has been described
for MS patients [147]. Another study found higher CSF levels of EVs in patients with
progressive forms of MS and in those with CIS. During relapses, there is an increase in the
number of EVs from the CSF but was associated with decreased number of CD19+/CD200+
EVs. In addition, the presence of MS lesions was correlated with an increase of CSF EVs that
were CD4+/CCR3+, CD4+/CCR5+, or CCR3+/CCR5+ [148]. During acute exacerbations
of MS, there is a release of microparticles of less than 1500 nm from endothelial cells that
express CD31, demonstrating endothelial dysfunction [149]. Higher levels of exosomes
that express MOG were present in patients with SPMS and in relapse of RRMS patients;
higher levels of MOG expression in exosomes also correlated with disease activity [150].
Additionally, exosomes from the plasma of MS patients and controls demonstrated a higher
amount of C16:0 sulfatide in those from MS patients [151]. EVs from MS patients have
also been found to have lower levels of TLR3 and higher levels of TLR4 compared to
controls [152]. Kallikrein B1 (KLKB1) and apolipoprotein-E4 (ApoE4) were also found to be
increased in the EVs of CSF compared to the CSF [153]. Acid-sphingomyelinase-enriched
exosomes have also been found to be correlated with disease severity [147].
9.6. Metabolomics
Studying metabolites in biofluids during disease states is emerging as a powerful
approach, as distinct metabolite signature could be a potential biomarker for disease
progression or predictive of the beneficial effect of DMTs in MS [154]. Few studies have
outlined a distinct metabolic signature, including serum phospholipids [155], altered bile
acid metabolism [156], abnormalities in aromatic amino acid metabolism [157], and proresolving lipid mediators in MS compared to healthy subjects, which could be developed
as a biomarker for disease and/or novel therapy. Moreover, altered metabolite signature
during disease relapse [158,159] could be developed as a metabolic biomarker for disease
progression in MS.
9.7. Metabolites and Gut Microbiome
With only a 30% concordance rate between monozygotic twins for MS, autoimmune
demyelination is a result of both genetics and the environment. An individual must have
a genetic susceptibility for MS and particular environmental factors that affect gene expression. A potential important environmental factor is an individual’s microbiome [160].
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Studies have found that intestinal microbiota may affect the brain’s physiology and behaviors as well as the peripheral [161] and CNS [162] immune compartments. Stool samples
provide readouts of the gut microbiota and may be useful in predicting the risk of relapse in
MS [163,164] because the intestinal microbiota can affect the permeability of the BBB [165]
and demyelination [166]. The microbiome of MS patients has been found to have higher
amounts of Pseudomonas, Mycoplama, Haemophilus, Blautia, and Dorea genera, while
the control group has higher amounts of Parabacteroides, Adlercreutzia, and Prevotella
genera [163]. Another study found that MS patients had higher levels of Saccharomyces
and Aspergillus, with the former being positively correlated with circulating basophils but
negatively correlated with regulatory B cells, and the latter being positively correlated with
activated CD16+ dendritic cells [167].
Pediatric MS patients without the gut phylum Fusobacteria have been found to have
a higher risk of relapse than those with Fusobacteria [168]. MS patients have also been
found to have decreased clostridial species in the gut microbiome, but they were not the
spore-forming clostridial species that induce Tregs to prevent autoimmunity, demonstrating
differences in clostridial species between MS and other autoimmune conditions [169].
The gut microbiota observed in MS patients also seemed to have decreased butyrate
producers [169]. Studies have shown that butyrate can increase Treg populations through
a short-chain fatty acid (SCFA) G-protein-coupled receptor and increase the production
of anti-inflammatory cytokines, such as IL-10 and IL-4, promoting an anti-inflammatory
state through IL-10 mediated activity of antigen-presenting cells (APCs) and T cells [170].
SCFAs were also found to be decreased in SPMS [170], so it may be a useful marker for
progressive disease. Although links have been drawn between the microbiome and other
neurodegenerative disorders [171], more studies are needed to determine if microbiota
signatures can distinguish MS from other diseases and whether there is a causal relationship
with microbiome disease activity in MS patients. A summary of this biomarker and the
ones discussed above in this section can be found in Table 6.
Table 6. Biomarkers of a Future Bioinformatics Approach.
Potential
Biomarker

Study Population (n)

Sample

Results

RRMS (65)

Peripheral
blood

DMF shifts the balance between Th1/Th17
and Th2 and reduces memory T cells in MS
patients, specifically decreasing the absolute
number of CD4+ and CD8+ T cells, while
increasing the CD4+/CD8+ ratio [56]

RRMS (36), SPMS (20),
PPMS (43), controls (45)

Whole
blood

T cell dysregulation in patients with
untreated MS [124]

Whole
blood

Siponimod treatment resulted in a decrease in
CD4+ T cells, CD8+ T cells but an increase in
Tem cells, Th2 cells, Tregs, and Bregs; affected
CD4+ more than CD8+, with a larger
reduction seen for Tn and Tcm than Tem [127]

RRMS (6)

Peripheral
blood

Abnormal NFkB gene expression in T cells,
out of 43 differentially expressed genes
between acute relapse and complete
remission, correlated most significantly with
MS relapse [128]

RRMS (5), SPMS (10),
PPMS (5), controls (24)

Peripheral
blood

After methylprednisolone pulse therapy, MS
patients had significantly lower levels of
DNA-binding p65 NFkB subunits compared
to that of healthy controls [130]

SPMS (36)
Cellular Studies

Possible Utility

Prognostic,
treatment
response
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Table 6. Cont.
Potential
Biomarker

Transcriptomics

Study Population (n)

Sample

Results

MS (39), controls (27)

CSF

Follicular T cells may drive B cell expansion
and infiltration in MS [133]

RRMS (16), CIS (2),
controls (3)

CSF

Polyclonal IgM and IgG1 B cells are polarized
towards an inflammatory, memory, and
plasma cell phenotype [134]

Serum

An overall upregulation of miRNAs that
promote anti-inflammation and
pro-regenerative polarization in MS patients;
miR-155 is downregulated in both PPMS and
RRMS and miR-124 downregulated in PPMS;
miR-23a, miR-30c, miR-125a, miR-146a, and
miR-223 are upregulated in both RRMS and
PPMS, but that miR-181a was only increased
in RRMS [138]

RRMS (21), PPMS (8)

miRNAs

CSF

miR-181c is associated with earlier conversion
of CIS to RRMS [139]

Cohort 1: RRMS (43),
CIS (34), controls (65)
Cohort 2: RRMS (96),
CIS (120), controls (214)

CSF

miR-150 has been found to be upregulated in
MS patients compared to controls; miR-150 is
associated with earlier conversion of
CIS to MS [140]

RRMS (4), controls (4)

Plasma

An increase in miRNA let-7i in the exosomes
of MS patients [146]

RRMS (21), OND (20)

CSF

Higher number of total exosomes in MS
patients; ASM-enriched exosomes correlated
with disease severity [147]

RRMS (35), progressive
MS (4), CIS (2), OIND (2),
ONIND (16)

CSF

Higher levels of EVs in patients with CIS and
progressive forms of MS; increase in the
number of EVs during relapse but decrease in
number of CD19+/CD200+ EVs; presence of
MS lesions is correlated with an increase of
CSF EVs that were CD+/CCR3+,
CD4+/CCR5+, or CCR3+/CCR5+ [148]

MS exacerbation (30), MS
remission (20), controls (48)

Plasma

Release of microparticles of less than 1500 nm
from endothelial cells that express CD31
during acute exacerbations [149]

RRMS (45), SPMS (30),
controls (45)

Serum

Higher levels of exosomes that express MOG
were present in patients with SPMS and in
relapse of RRMS patients; higher levels of
MOG expression in exosomes also correlated
with disease activity [150]

RRMS (8), SPMS (1),
controls (9)

Plasma

Exosomes from MS patients have increased
C16:0 sulfatides compared to controls [151]

RRMS (18), controls (16)

Serum

EVs from MS patients have lower levels of
TLR3 but higher levels of TLR4 compared to
controls [152]

RRMS (4), controls (3)

CSF

KLKB1 and ApoE4 are increased in EVs of
CSF compared to the CSF [153]

CIS (58)

EVs

Possible Utility

Prognostic

Predictive,
prognostic

Prognostic
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Table 6. Cont.
Potential
Biomarker

Metabolomics

Study Population (n)

Sample

Results

RRMS (24), controls (30)

Plasma

Decreased levels of PC(34:3), PC(36:6),
PE(40:10) and PC(38:1) phospholipids [155]

RRMS (106), PMS (176),
controls (127), pediatric MS
(31), pediatric controls (31)

Plasma

Decreased secondary bile acids [156]

MS (637), controls (317)

Plasma

Alteration in aromatic amino acid
metabotoxins [157]

Plasma

Identified metabolic signature
consist of hormones, lipids, and amino
acids associated with MS and with a severe
disease course [158]

Plasma

Identified four metabolites including lysine,
asparagine, isoleucine, and leucine, which
showed a consistent trend with time away
from relapse [159]

Microbiome

MS patients had higher amounts of
Pseudomonas, Mycoplama, Haemophilus,
Blautia, and Dorea genera, while the control
group had higher amounts of Parabacteroides,
Adlercreutzia, and Prevotella genera [163]

RRMS (21), SPMS (1),
PPMS (2), controls (22)

Microbiome

MS patients had higher levels of
Saccharomyces and Aspergillus, with the
former being positively correlated with
circulating basophils but negatively
correlated with regulatory B cells, and the
latter positively correlated with activated
CD16+ dendritic cells [167]

Pediatric RRMS (17)

Microbiome

Absence of Fusobacteria is associated with
quicker relapse compared to the presence of
Fusobacteria [168]

RRMS (20) controls (58)

Microbiome

Decreased cloistral species and butyrate
producers in MS patients [169]

SPMS (20), controls (15)

Plasma

SCFAs were also found to be
decreased in SPMS [170]

Retrospective longitudinal
cohort: MS (238),
controls (74)
Prospective cohort:
MS (61), controls (41)
RRMS in relapse (38), last
relapse (LR) between 1 to
6 months (28), LR between
6–24 months (34); LR more
than 24 months ago (101)

RRMS (31), controls (36)

Metabolites and
microbiome

Possible Utility

Prognostic

Prognostic

miRNAs = micro-RNAs, EVs = extracellular vesicles; DMF = dimethyl fumarate; NFkB = nuclear factor kappa beta;
Th = T helper; Tem = effector memory T cells; Tregs = regulatory T cells; Bregs = regulatory B cells; Tn = naïve T
cells; Tcm = central memory T cells; Ig = immunoglobulin; ASM = acid sphingomyelinase; TLR = toll-like receptor;
KLKB1 = kallikrein B1; ApoE4 = apolipoprotein-E4; PC = phosphatidylcholine; PE = phosphatidylethanolamine;
SCFAs = short-chain fatty acids.

10. Conclusions
With the search for biomarkers with more prognostic value in detecting MS relapse
and progression, there have been exciting advances with NfL. However, NfL levels can be
difficult to use when clinically evaluating individual patients, especially when monitoring
relapse or disease progression. In addition to the many confounding variables, such as age,
body mass index (BMI), and blood volume, NfL indicates neuronal damage and, thus, is
nonspecific to MS. Elevated NfL also does not distinguish between patients with MS and
those with minor head trauma, infection, other neurological diseases, or comorbidities, such
as diabetes. Additionally, when patients have a sudden spike in their NfL levels, it is usually
indicative of inflammation and active lesions. Hence, increases in NfL levels may be more
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indicative of neuroinflammation than neurodegeneration in MS. Other biomarkers of axonal
damage, neuronal damage, glial dysfunction, demyelination, and inflammation described
in this review are plagued by similar issues as NfL and are limited by conflicting results
from various studies. Therefore, a combination of diverse biomarkers (protein, immune
cells, transcriptomics, extracellular vesicles, metabolites, microbiome, etc.) coupled with
state-of-the-art bioinformatics are needed to develop useful biomarker tools to predict true
relapse and disease progression for MS patients (Figure 1). New technology like proteomics,
metabolomics, and sc-RNA seq may greatly aid in the discovery of novel biomarkers and
therapeutic targets for disease progression in MS.
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